View Older Stories View More Recent Stories
-
Trump: tariffs will get countries to agree to drug pricing plan
-
BMO Capital on Novo Nordisk (NVO): 'still give the competitive edge to Lilly following this week'
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put
-
Eli Lilly's orforglipron outperforms oral semaglutide in diabetes trial
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY), full ATTAIN-1 data 'broadly positive'
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY)
-
Berenberg Downgrades Eli Lilly (LLY) to Hold
-
FDA issues warning letter to Eli Lilly over ZEPBOUND promotional video
-
FDA warns Eli Lilly over misleading weight-loss drug promotion
-
Eli Lilly plans $5 billion Virginia manufacturing facility
-
How are GLP-1 drugs changing U.S. grocery behavior?
-
Novo Nordisk's Wegovy may quiet thoughts about food, study shows; shares up
-
Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Eli Lilly launches AI platform for biotech drug discovery
-
Lilly's Jaypirca shows improved survival in treatment-naive CLL study
-
FDA grants breakthrough therapy status to Lilly's lung cancer drug olomorasib
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
-
BMO Capital: 'Eli Lilly (LLY) Shares Expected to Trade Higher Post ATTAIN-1 Data'
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Lilly's Verzenio shows survival benefit in breast cancer trial
-
HSBC Upgrades Eli Lilly (LLY) to Hold
-
TD Cowen on Eli Lilly (LLY): 'Orfo Successful In ATTAIN-2, Regulatory Submission Underway; Model Updated'
-
William Blair on Orforglipron: 'It is therefore our opinion that orforglipron could be seamlessly incorporated into patients’ daily routines'
-
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY), 'early innings in obesity still'
-
Immuneering secures clinical supply deal with Lilly for cancer drug combo
-
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-
JPMorgan on Viking Therapeutic (VKTX): 'we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile'
-
Mizuho: Viking (VKTX) Oral Obesity Program is 'Quite Discouraging'
-
Lilly signs up to $1.3 billion deal with Superluminal for obesity drugs
-
Eli Lilly (LLY) PT Lowered to $825 at Cantor Fitzgerald
-
Eli Lilly (LLY) PT Lowered to $875 at Guggenheim
-
Eli Lilly & Co. (LLY) CEO buys $1 million in stock
-
What to do with Novo Nordisk shares after recent volatility? Barclays explains
-
Eli Lilly & Co. (LLY) sued by Texas for allegedly bribing providers to prescribe company's medications
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
Bernstein Sees 'Clear Buying Opportunity' for Eli Lilly (LLY)
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Lowered to $895 at UBS
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
-
Eli Lilly & Co. (LLY) options active on 358K contracts as share price pullback
-
Eli Lilly (LLY) PT Lowered to $905 at Jefferies
-
Leerink Partners Downgrades Eli Lilly (LLY) to Market Perform, 'we no longer expect upward pressure on long-term consensus expectations'
-
Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
-
BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk shares jump as Eli Lilly obesity pill disappoints
